Semaglutide already lowers blood sugar by enhancing insulin, so combining these effects can cause severe hypoglycemiashakiness, confusion, rapid heartbeat, or loss of consciousness
Older age is a strong predictor for poor outcome in intracerebral haemorrhage: the INTERACT2 study
Wegovy (semaglutide) functions by targeting the GLP-1 receptor to assist in appetite regulation and weight management
Some people may also develop severe gastrointestinal problems like bowel obstruction
Clinical studies show that these medications promote safe, sustainable fat reduction, emphasizing long-term weight management and overall health improvement rather than rapid, short-term results
While this was one of the few large, real-world studies to examine the effectiveness of semaglutide 2.4 mg treatment on weight and cardiometabolic outcomes at 12 months [19], causality could not be established, and the study did not account for all potential confounders, such as lifestyle or behavioral factors